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Abstract
Background
The Healthy Activity Programme (HAP), a brief behavioural intervention delivered by lay
counsellors, enhanced remission over 3 months among primary care attendees with depres-
sion in peri-urban and rural settings in India. We evaluated the sustainability of the effects
after treatment termination, the cost-effectiveness of HAP over 12 months, and the effects
of the hypothesized mediator of activation on clinical outcomes.
Methods and findings
Primary care attendees aged 18–65 years screened with moderately severe to severe
depression on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP
plus enhanced usual care (EUC) (n = 247) or EUC alone (n = 248), of whom 95% completed
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assessments at 3 months, and 91% at 12 months. Primary outcomes were severity on the
Beck Depression Inventory–II (BDI-II) and remission on the PHQ-9. HAP participants main-
tained the gains they showed at the end of treatment through the 12-month follow-up (differ-
ence in mean BDI-II score between 3 and 12 months = −0.34; 95% CI −2.37, 1.69; p = 0.74),
with lower symptom severity scores than participants who received EUC alone (adjusted
mean difference in BDI-II score = −4.45; 95% CI −7.26, −1.63; p = 0.002) and higher rates of
remission (adjusted prevalence ratio [aPR] = 1.36; 95% CI 1.15, 1.61; p < 0.009). They also
fared better on most secondary outcomes, including recovery (aPR = 1.98; 95% CI 1.29,
3.03; p = 0.002), any response over time (aPR = 1.45; 95% CI 1.27, 1.66; p < 0.001), higher
likelihood of reporting a minimal clinically important difference (aPR = 1.42; 95% CI 1.17,
1.71; p < 0.001), and lower likelihood of reporting suicidal behaviour (aPR = 0.71; 95% CI
0.51, 1.01; p = 0.06). HAP plus EUC also had a marginal effect on WHO Disability Assess-
ment Schedule score at 12 months (aPR = −1.58; 95% CI −3.33, 0.17; p = 0.08); other out-
comes (days unable to work, intimate partner violence toward females) did not statistically
significantly differ between the two arms. Economic analyses indicated that HAP plus EUC
was dominant over EUC alone, with lower costs and better outcomes; uncertainty analysis
showed that from this health system perspective there was a 95% chance of HAP being
cost-effective, given a willingness to pay threshold of Intl$16,060—equivalent to GDP per
capita in Goa—per quality-adjusted life year gained. Patient-reported behavioural activation
level at 3 months mediated the effect of the HAP intervention on the 12-month depression
score (β = −2.62; 95% CI −3.28, −1.97; p < 0.001). Serious adverse events were infrequent,
and prevalence was similar by arm. We were unable to assess possible episodes of remis-
sion and relapse that may have occurred between our outcome assessment time points of 3
and 12 months after randomisation. We did not account for or evaluate the effect of media-
tors other than behavioural activation.
Conclusions
HAP’s superiority over EUC at the end of treatment was largely stable over time and was
mediated by patient activation. HAP provides better outcomes at lower costs from a per-
spective covering publicly funded healthcare services and productivity impacts on patients
and their families.
Trial registration
ISRCTN registry ISRCTN95149997
Author summary
Why was this study done?
• Depression is the leading mental health contributor to the global burden of disease.
• Access to effective treatments is low globally, but especially so in low- and middle-
income countries like India, where a recent national survey reported a treatment gap of
85%.
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• The Healthy Activity Programme (HAP) is a brief psychological treatment based on the
principles of behavioural activation and delivered by non-specialist providers; we have
earlier reported the effectiveness of this intervention in reducing depressive symptoms
and promoting remission at the end of treatment.
• The aim of the present study was to evaluate the sustained effectiveness and the cost-
effectiveness of HAP over 12 months and to assess whether behavioural activation
reported by patients at 3 months mediated the effects of the intervention on depression
at 12 months.
What did the researchers do and find?
• We implemented a randomised controlled trial in which 493 adult primary health-care
attendees with moderately severe or severe depression were assigned to either the HAP
treatment plus enhanced usual care (EUC) (n = 245) or EUC alone (n = 248); those
assigned to HAP received treatment over 2 to 3 months.
• HAP participants maintained the gains they showed at the end of treatment through the
12-month period, with lower symptom severity scores than participants who received
EUC alone and higher rates of remission; these effects were partly mediated by increased
levels of behavioural activation reported at 3 months.
• HAP was highly likely to be cost-effective, and could even save money if productivity
costs were taken into account.
What do these findings mean?
• HAP is associated with sustained effects on depression outcomes over a 12-month
period and represents good value for money.
• HAP is ideally suited for scaling up to reduce the treatment gap for depression.
Introduction
Depression is a major contributor to the global burden of disease [1], and its treatment is a pri-
ority in the global health agenda. Despite the well-documented health and economic conse-
quences of depression [2,3], investments in mental health are inadequate, resulting in a large
treatment gap [3]. Access to treatment remains a challenge, particularly in low- and middle-
income countries (LMICs). The recent National Mental Health Survey in India reported a
treatment gap of 85% for major depression [4]. Psychological treatments (PTs) are recom-
mended as first-line interventions [5], not only because they are as efficacious as pharmacolog-
ical treatments, but also because they produce sustained effects after treatment termination
[6]. However, there are questions about the generalisability of PTs in LMICs, where the lack of
trained professionals, variations in explanatory models, and lower literacy may present struc-
tural barriers to PT [7,8]. Some of these barriers could be overcome by the innovative use of
task-sharing, and there is growing evidence for the acceptability and effectiveness of contextu-
ally sensitive PTs delivered by appropriately trained and supervised lay health workers in
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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primary care and community settings [9–11]; however, there are very few trials that have
reported on the sustained effects, cost-effectiveness, or mediation of the effects of these
treatments.
The PRogram for Effective Mental health Interventions in Under-resourced health systeMs
(PREMIUM) was designed to (1) implement a methodology for the development of scalable
PTs that are culturally appropriate, affordable, and feasible for delivery by non-specialist
health workers and (2) evaluate the effectiveness and cost-effectiveness of PTs for the 2 leading
mental health causes of the burden of disease, the Counselling for Alcohol Problems (CAP)
programme for harmful drinking [12] and the Healthy Activity Programme (HAP) for moder-
ately severe to severe depression [13,14]. The HAP treatment is adapted from behavioural acti-
vation, a treatment which has a strong theoretical and empirical evidence base across diverse
contexts and patient populations [15]. The stance of behavioural activation is particularly
attractive as it focuses on the link between activities and mood, whilst emphasising increased
activation and engagement, problem solving skills, and enhanced social support. A core feature
of PREMIUM was the delivery of both treatments by the same lay counsellors in routine pri-
mary care settings, as they would be used in actual clinical practice. Usual care in primary care
for depression in India is, in effect, no care at all. This was confirmed in the study setting dur-
ing the pilot study. This is primarily because most cases are not diagnosed, and, amongst indi-
viduals who are diagnosed, most receive neither antidepressants nor PT.
Previously, we reported the favourable results of the impact of 6–8 sessions of HAP on men-
tal health and secondary outcomes at the primary 3-month post-enrolment endpoint [16]. The
key findings were that HAP produced significantly lower symptom severity (adjusted mean
difference [AMD] in Beck Depression Inventory–II [BDI-II] score = −7.57; 95% CI −10.27,
−4.86) and higher remission rate (adjusted prevalence ratio [aPR] = 1.61; 95% CI 1.34, 1.93).
HAP also showed superior results on the secondary outcomes of disability, days out of work,
and intimate partner physical violence in women. The incremental cost of HAP per quality-
adjusted life year (QALY) gained was Intl$9,333 (95% CI Intl$3,862, Intl$28,169), with an 87%
chance of being cost-effective from a health system perspective in the study setting.
The question now becomes whether these effects were sustained following the end of treat-
ment—in a disorder that is highly prone to relapse and recurrence—given HAP’s relatively
brief duration, minimal dosage, and delivery by non-specialised workers (most brief PTs, par-
ticularly behavioural-activation-based treatments in high-income countries, typically involve
at least twice this number of sessions, delivered by highly trained professionals). In addition, a
meaningful sustained effect should be accompanied by a patient-defined clinically important
improvement in symptoms, as well as evidence that the mediating factor targeted by the PT
accounted for the PT’s effects. In this paper, we address 3 novel questions: the stability of
HAP’s effects on depression and other outcomes at 12 months post-enrolment, the mediation
of the clinical outcomes by patient activation assessed at 3 months, and the cost-effectiveness
of the intervention over 12 months.
Methods
The methods are described in detail in the protocol (S1 Protocol). The trial was conducted in
accordance with the protocol (ISRCTN95149997) [17], which was approved by the trial steer-
ing committee. Approval for the conduct of the trial was obtained from the institutional review
boards of the London School of Hygiene & Tropical Medicine, Sangath (the implementing
institution in India), and the Indian Council of Medical Research. Written (or witnessed, if the
participant was illiterate) informed consent was mandatory for enrolment. This study is
reported as per CONSORT guidelines (S1 CONSORT Checklist).
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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Study design and participants
This was a parallel-arm, individually randomised controlled trial in 10 primary health centres
in Goa, a state on the west coast of India. Participants were adult primary health centre (PHC)
patients aged 18–65 years with a probable diagnosis of moderately severe to severe depression
ascertained with a Patient Health Questionnaire 9 (PHQ-9) score > 14, a cut-point previously
validated in the study setting, and who gave informed consent. Pregnant women, patients pre-
senting with severe medical conditions requiring urgent medical attention, and those with
hearing/speech difficulties were excluded. Participants were interviewed to collect data on
socio-demographic factors and potential moderators of treatment outcome: sex, illness sever-
ity, duration of the illness, and expectations for treatment [18]. Sequential numbered opaque
envelopes were used to randomise consenting participants in a 1:1 allocation scheme [19].
Enrolment was conducted between 28 October 2013 and 29 July 2015, and the final 12-month
assessment was completed on 30 August 2016.
Sample size estimation
Our sample size estimations for the 3-month primary outcomes assumed an intra-cluster corre-
lation between PHCs of 0.04, with 1 counsellor per PHC at any one time, loss to follow-up of
15% over 3 months, and a 1:1 allocation ratio. Based on these assumptions, we aimed to recruit
500 participants (425 in our analysis sample) to detect the hypothesized effects: (1) a standard-
ised mean difference (effect size [ES]) of 0.42 for the primary continuous outcome of depression
severity, with 90% power, and (2) a proportion recovered of 65% in the HAP plus enhanced
usual care (EUC) arm compared with 44% in the EUC arm, with 92% power. The high follow-
up rate (attrition rate of 9%) at 12 months means that we have 90% power to detect these ESs at
12 months.
Interventions
Enhanced usual care. EUC comprised routine consultation with the PHC physician,
enhanced by providing the PHQ-9 screening results to both the PHC physician and the
patient, and providing copies of a contextualised version of the WHO Mental Health Gap
Action Programme (mhGAP) guidelines to the PHC physician that included information on
when and where to refer for psychiatric care [20]. EUC was available to all trial participants.
Healthy activity programme. HAP is a contextually adapted brief PT based on beha-
vioural activation [13] that focuses on increasing patient activation levels in pleasurable or
mastery activities, and comprises the following strategies: psychoeducation, behavioural assess-
ment, activity monitoring, activity structuring and scheduling, activation of social networks,
and problem solving. HAP was delivered in an individual format and involved 6–8 sessions,
each lasting 30–40 minutes, with the initial sessions being at weekly intervals. The PT consisted
of three phases: a beginning phase focused on orienting to treatment, a multi-session middle
phase on teaching core intervention strategies, and a late phase on reviewing gains and termi-
nation. The middle phase could be extended with up to 2 additional sessions for patients who
did not show sufficient improvement, allowing a maximum of 8 sessions across all phases.
Patients who did not respond by the end of treatment were referred for specialist care. Details
about the intervention are reported elsewhere [13] and can be accessed online (http://hap.
nextgenu.org). A description of counsellor selection, training, and supervision is published
elsewhere [13,21]. Counsellors were members of the local community, were above 18 years of
age, had completed at least high school education, and did not have prior professional mental
health training. Counsellors underwent a 3-week participatory workshop covering both PTs
(HAP and CAP), followed by an internship phase of 6 months, in which trainee counsellors
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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delivered the treatment to eligible patients in PHCs. Eleven counsellors who met competency
standards participated in the trial. They received weekly peer-led supervision in groups of 4–6
and individual supervision twice monthly.
The same counsellor delivered the HAP treatment to individuals with depression and the
CAP treatment to adult males who met criteria for harmful drinking. Counsellors maintained
separate clinical registers for the 2 groups of patients and reviewed individual patient records
before each session. In order to ensure that their treatment-specific counselling skills were
maintained throughout the trial, weekly peer-led group supervision sessions were structured
in ways that involved holding separate sessions for each of the 2 treatments. This arrangement
allowed the expert supervisors for each of the 2 treatments to provide more focused feedback
to the counsellors.
Treatment fidelity was assessed at 2 levels: the quality with which HAP was delivered and
the quantity of the dose of HAP administered. The quality of HAP was assessed based on a
random selection of 10% of audio-recorded sessions, rated on a therapy quality scale [21] by
peers and experts. The quantity of HAP delivered was assessed based on treatment completion
records maintained by the counsellors.
Outcomes
The 2 primary outcomes for the 12-month analyses were (1) depression severity assessed by
BDI-II (dropping the item related to sex for cultural reasons) and (2) remission from depres-
sion (defined as PHQ-9 score < 10). Our PHQ-9 cutoff for remission is in alignment with the
depression treatment literature, which defines remission as either the complete absence of
symptoms, which is reflected by a PHQ-9 score < 5, or a partial absence of symptoms, defined
as PHQ-9 score < 10 [22,23]. A range of secondary outcomes included recovery from depres-
sion (PHQ-9 score< 5 at both 3 and 12 months), relapse (partial or full), disability (WHO Dis-
ability Assessment Schedule 2.0 [WHODAS 2.0]), suicidal behaviour, and intimate partner
violence.
We estimated the minimal clinically important difference (MCID) as a patient-centred met-
ric that captures both the magnitude of improvement and the value the patient places on that
improvement [24]. We used the anchor-based approach for estimating MCID that ties change
in outcome on the PHQ-9 to the patient’s subjective sense of improvement [25]; patients’ rat-
ing of perceived improvement on a ‘global rating of change’ scale [26] was used to calculate the
corresponding difference in score (see S1 Table for definition of all secondary outcomes). In
addition, we assessed patient-reported activation levels at 3 months, using a 5-item Likert scale
(0–5) based on the Behavioral Activation for Depression Scale–Short Form (BADS-SF) [27], to
test for mediation. This behavioural activation variable was pre-specified as a potential media-
tor of HAP on depression outcomes because patient activation levels are the primary focus of
treatments for depression based on the theory of behavioural activation. All measures were
carefully selected based on their psychometric properties and contextual appropriateness. The
BDI-II is a widely used measure for evaluating depression in trials, and has been used in sur-
veys in India [28]. The PHQ-9 has been validated in primary care, and a Konkani (widely spo-
ken local language in trial area) version validated in Goa [29]. WHODAS 2.0 is validated for
international use and was used in previous trials in Goa [30,31]. The Client Service Receipt
Inventory (CSRI), which was used to collect information on health service use for the eco-
nomic evaluations, has been previously used in trials in the study setting [32,33]. The 2 items
on intimate partner violence were selected based on interviews used in earlier studies in Goa
[34], and the BADS-SF was translated into Konkani using standardised procedures followed
by piloting [13].
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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Statistical methods
Analyses were on an intention-to-treat basis using multiple imputations (20 iterations) for
missing outcome data via a data augmentation algorithm in Stata 14.0. All models adjusted for
baseline PHQ-9 score and for PHC as a fixed effect to allow for within-PHC clustering. For
continuous outcomes, intervention effects were estimated using linear regression and are
reported as AMDs or ESs with 95% CIs. For binary outcomes, intervention effects are reported
as aPRs estimated from logistic regression using the marginal standardisation technique for
the prevalence ratios and the delta method for the CIs [35]. Sensitivity analyses included
adjustment for counsellor as a random effect and complete case analyses. Repeated measures
analyses were conducted to estimate the time-by-treatment interaction effect. In addition, we
examined changes in mean outcome scores over time, by treatment condition. The MCID was
estimated using receiver operating characteristic (ROC) analysis in order to establish the mini-
mum relative change in PHQ-9 score that best differentiated those individuals who felt better
from those who did not. We applied the cut-point for minimum specificity of 70% suggested
by Button and colleagues [25]. Following cut-point determination, a binary outcome variable
was created, and intervention effects reported as aPRs estimated from logistic regression.
Results are described in terms of strength of evidence rather than statistical significance;
hence, we did not adjust p-values for multiple comparisons [36]. Our approach to the media-
tion analysis involved the Monte Carlo method for assessing mediation [37,38], which has
been shown to be more rigorous than the Sobel test and as accurate as bootstrapping [39]. In
the current study, we computed a 95% CI with 20,000 repetitions. All regression models con-
trolled for individual patients’ baseline PHQ-9 score as well as any variables that were found to
be significantly related to either the proposed mediator or 12-month BDI-II score. The vari-
ance inflation factor (VIF) was calculated for each independent variable that was entered into
each regression model to assess multicollinearity between independent variables, with a con-
servative cutoff for defining multicollinearity (VIF 5).
Economic evaluations were conducted from both the healthcare system perspective (costs
to the health system only) and the societal perspective (health system costs plus impacts on the
productivity of patients and their families). Information on the use of health services, including
contacts with PHCs, hospital doctor contacts and inpatient stays, medication use, and diagnos-
tic tests, was collected from service users using a tailored version of the CSRI at 3 and 12
months. Unit costs for doctor contacts and inpatient stays were inflated to 2015 prices using
unit costs that had previously been used for an economic evaluation in Goa [40]. Detailed
information on medications and laboratory tests used and costs to the public purse were
recorded. Mean costs were then extrapolated to cover the full 12 months. Detailed information
was also recorded on the time taken to deliver each HAP session, whether delivered at a PHC,
over the telephone, or at a patient’s home. Travel time and transportation costs were also
recorded for home visits, including ‘no show’ home visits. Per minute unit costs for counsel-
lors, taking account of their training, supervision, and other overheads, were then attached to
time to estimate the total costs of intervention delivery.
Productivity costs consisted of patient time out of usual activities because of their health, as
well as time costs for patients (and accompanying family members) related to the use of health
services. The number of days completely out of normal role (i.e., days unable to work) over the
previous 30 days was based on patient responses to the WHODAS 2.0 at 3 months and 12
months. WHODAS 2.0 data on days of activity cutback over this period were also included,
with the assumption that each day of cutback would have half the value of a complete day out
of role, an approach that has been adopted in high-income settings [41]. Patients reported how
much time was spent attending health services using the CSRI; patients were also asked to
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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report if they were accompanied by someone. If so, it was also assumed that 1 family member
incurred the same level of productivity loss. We assumed that the mean of patient and family
time costs at 3 months and 12 months would also apply to the rest of the year. Costs due to cut-
back and complete days out of role were adjusted to avoid double counting time that patients
spent attending health services. All patient and family time was valued using the human capital
approach making use of different daily wage rates recommended in 2015 by the Indian Office
of the Labour Commissioner. The rate used was dependent on whether the patient was classi-
fied as an unskilled, skilled, or clerical/professional worker. We assumed the value of days out
of role for those classified as unemployed was the same as that for unskilled workers.
QALYs were derived through transformation of WHODAS 2.0 12-item scores, as in earlier
Indian trials [40]. Incremental cost-effectiveness ratios (ICERs) were bootstrapped, randomly
resampling pairs of outcomes and costs for intervention and comparator groups to derive 95%
CIs, with a distribution of mean incremental costs and effects shown on cost-effectiveness
planes to test the robustness of cost results. Cost-effectiveness acceptability curves were also
generated, showing the likelihood that HAP would be cost-effective at different levels of will-
ingness to pay. Statistical analyses were conducted using Excel 2016 and SPSS 21 for the cost-
effectiveness analyses, SAS and R-Studio for the mediation analyses, and STATA 13/14 for all
other analyses. All costs are presented in 2015 international dollars (http://eppi.ioe.ac.uk/
costconversion/).
Results
Trial conduct
A detailed description of the conduct of the trial is provided in the primary trial paper [16].
Between 28 October 2013 and 29 July 2015, 34,306 (23%) of the 146,661 PHC attendees assessed
met inclusion/exclusion criteria. Of these, 31,888 adult PHC attendees were screened for
depression using the PHQ-9, of whom 785 (2.5%) were eligible (PHQ-9 score> 14) for inclu-
sion in the trial, and 495 (63%) consented to participate and were enrolled. A total of 248 partic-
ipants were randomised to EUC, and 247 to HAP plus EUC. Of the latter, 2 were subsequently
excluded (1 withdrew consent and 1 was erroneously enrolled in both trials), leaving a total of
245 participants treated with HAP plus EUC (Fig 1). The modal reason for non-participation
was lack of time, and participants had similar baseline characteristics to non-participants. Base-
line characteristics were similar by arm. In all, 466 participants (95%) were assessed at the
3-month post-enrolment endpoint, and 447 participants (91%) at the 12-month follow-up; rates
were similar between arms. A total of 438 (89%) participants had observations for both follow-
up time points. In all, only 18 (3.6%) participants did not have any follow-up data. Those lost to
follow-up at 12 months were younger (S2 Table), and this was similar at the 3-month post-
enrolment endpoint. The intra-cluster correlation of BDI-II within PHCs was 0.02.
Impact on clinical outcomes
There was an intervention effect on both primary outcomes at the 12-month follow-up. The
mean endpoint BDI-II score was 19.73 (SD 15.53) among participants in the HAP plus EUC
arm and 24.09 (SD 14.67) among participants in the EUC arm (AMD = −4.45; 95% CI −7.26,
−1.63; ES = 0.23; 95% CI 0.18, 0.28; p = 0.002; Table 1). This main effect at 12 months was
influenced by the passage of time (p-value for time-by-treatment interaction = 0.04), such that
participants in the EUC arm continued to improve through the 12-month follow-up (differ-
ence in mean BDI-II score between 3 and 12 months = 3.2; 95% CI 1.34, 5.06; p = 0.001; S3
Table) while participants in the HAP plus EUC arm essentially retained the greater gains that
they had made at the earlier assessment (difference in mean BDI-II score between 3 and 12
Sustained effects of a lay-counsellor-delivered brief psychological treatment for depression
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Fig 1. The healthy activity programme trial flow chart. CAP, Counselling for Alcohol Problems; EUC, enhanced usual care; HAP, Healthy Activity
Programme; PHQ-9, Patient Health Questionnaire 9.
https://doi.org/10.1371/journal.pmed.1002385.g001
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months = −0.34; 95% CI −2.37, 1.69; p = 0.74; S3 Table). Participants in the HAP plus EUC
arm also had a higher probability of remission than those in the EUC arm (63% versus 48%;
aPR = 1.36; 95% CI 1.15, 1.61; p< 0.001). As was the case for mean scores on the BDI-II,
remission rates stayed relatively constant from 3 to 12 months among participants in the HAP
plus EUC arm, whereas those in the EUC arm showed a slight increase by 12 months (Fig 2).
Sensitivity analysis showed similar results (S4 Table). There was no evidence of moderation by
sex, illness severity, duration of illness, or patient expectations (S5 Table).
Participants in the HAP plus EUC arm had a higher probability of remission and recovery
compared to those in the EUC arm (Table 1). While participants in the HAP plus EUC arm
who had remitted at 3 months had a higher probability of partial relapse at 12 months com-
pared to those in the EUC arm, the proportion with full relapse was similar between arms
(Table 1). Participants in the HAP plus EUC arm also had a higher probability of any response
over the 12 months (Table 1; Fig 3). More participants remitted in the HAP plus EUC arm in
the short term compared to the EUC alone arm, but, as expected, participants who remitted in
the HAP plus EUC arm were more likely to relapse following treatment termination than
patients who remitted in the EUC alone arm (Fig 3). Participants in the HAP plus EUC arm
Table 1. Effects of HAP plus EUC compared with EUC alone on primary and secondary clinical outcomes at 12 months.
Outcome EUC arm (n =
248)
HAP + EUC arm (n =
245)
Measure: point estimate (95% CI)1 p-Value
Primary outcomes at 12 months
Mean BDI-II score (SD)* 24.09 (14.67) 19.73 (15.53) AMD: −4.45 (−7.26, −1.63); ES: 0.23 (0.18,
0.28)
0.002
Remission: PHQ-9 score < 10** 117 (46.98%) 155 (63.14%) PR: 1.36 (1.15, 1.61); PD: 16.66% (7.85%,
25.47%)
<0.001;
<0.001
Secondary outcomes at 12 months
Recovery: PHQ-9 score < 5 at 3 and 12
months***
33 (13.27%) 64 (26.10%) PR: 1.98 (1.29, 3.03); PD: 12.96% (5.31%,
20.61%)
0.002; 0.001
Full relapse: PHQ-9 score = 15–27*** 12 (4.92%) 21 (8.78%) PR: 1.79 (0.87, 3.69) 0.14
Partial relapse: PHQ-9 score = 10–14*** 7 (2.70%) 21 (8.60%) PR: 3.19 (1.27, 7.88) 0.01
Mean PHQ-9 score (SD***) 10.46 (7.54) 8.16 (6.96) AMD: −2.36 (−3.70, −1.02); ES: 0.37 (0.32,
0.42)
<0.001
Any response over 12 months 266 (53.97%) 383 (77.65%) PR: 1.45 (1.27, 1.66) <0.001
Suicidal behaviour# 66 (26.55%) 47 (19.10%) PR: 0.71 (0.51, 1.01) 0.06
MCID (percent reduction in baseline PHQ-9
score)$
102 (41.25%) 142 (58.10%) PR: 1.42 (1.17, 1.71); PD: 17.08% (7.89%,
26.26%)
<0.001;
<0.001
Data given as number (percent) unless otherwise indicated.
1AMD adjusted for primary health centre as a fixed effect and PHQ-9 baseline score.
*Sensitivity analysis AMD point estimate (95% CI): random effects, −4.41 (−7.21, −1.61); complete case, −4.57 (−7.34, −1.81); excluding unmasked
(3.7%), −4.40 (−7.29, −1.51).
**Sensitivity analysis PR point estimate (95% CI): complete case, 1.36 (1.14, 1.61).
***Not previously specified in trials protocol but specified in published analysis plan.
#Suicidal thoughts over the past 2 weeks were assessed through the relevant PHQ-9 item while suicide attempts were assessed over the 3-month period
leading up to the 12-month outcome follow-up assessment. Suicide attempts were not included because the numbers were very small (only 2 patients [1 in
each arm] reported suicide attempt over the period).
$Estimated based on relative difference in baseline and outcome score, and how this compares with overall subjective global rating of ‘feeling better’ at the
end of the trial. The optimal cutoff in relative change in score with maximum specificity (>70%) was 55.
AMD, adjusted mean difference; BDI-II, Beck Depression Inventory–II; ES, effect size; EUC, enhanced usual care; HAP, Healthy Activity Programme;
MCID, minimal clinically important difference; PD, prevalence difference; PHQ-9, Patient Health Questionnaire 9; PR, prevalence ratio.
https://doi.org/10.1371/journal.pmed.1002385.t001
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had marginally lower prevalence of suicidal behaviour (mainly suicide thoughts as there were
only 2 suicide attempts) at 12 months. Our analysis of what constitutes a MCID yielded a rela-
tive score change of 55% from baseline. Based on this score change, HAP plus EUC was supe-
rior to EUC at 12 months (aPR = 1.42; 95% CI 1.17, 1.71; p< 0.001; Table 1).
Fig 2. Remission rates over time in the HAP plus EUC and EUC arms. EUC, enhanced usual care; HAP,
Healthy Activity Programme; PHQ-9, Patient Health Questionnaire 9.
https://doi.org/10.1371/journal.pmed.1002385.g002
Fig 3. Clinical trajectories in cases with 3- and 12-month outcome data (n = 438). EUC, enhanced usual
care; HAP: Healthy Activity Programme.
https://doi.org/10.1371/journal.pmed.1002385.g003
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Other outcomes and mediation analyses
HAP plus EUC had a marginal effect on WHODAS 2.0 score at 12 months (aPR = −1.58; 95%
CI −3.33, 0.17; p = 0.08); other outcomes (days unable to work, intimate partner violence
toward females) did not statistically significantly differ between the two arms (Table 2). The
prevalence of serious adverse events (HAP plus EUC arm, 23; EUC arm, 23) and proportion of
participants prescribed antidepressant medications (ADMs) (HAP plus EUC arm, 7; EUC
arm, 11) did not differ between the treatments (S6 Table). Our assessment of mediation dem-
onstrated that patient-reported behavioural activation level at 3 months partially mediated the
superiority of HAP plus EUC relative to EUC in terms of reduced depression severity at 12
months (β = −2.62; 95% CI −3.28, −1.97; p< 0.001; Fig 4; also S7 Table). Patient-reported
behavioural activation could account for 58% of the total effect of HAP plus EUC. None of the
models evidenced multicollinearity between the independent variables (VIF < 5).
Of the 245 participants in the HAP plus EUC arm (receiving a total of 1,181 HAP sessions),
169 (69%) had a planned discharge, of whom 7 (4%) were referred for specialist care. The
median number of sessions was 6 (IQR 5 to 7). Patients with an unplanned discharge were
likely to stop attending early (median 1 session [IQR 0 to 2]).
Costs and cost-effectiveness
While the health system costs of HAP + EUC were significantly higher than those of EUC alone
at 3-month follow-up due to the cost of providing HAP, by 12 months these costs were offset by
reductions in the use of health services through month 12, and there was no statistically signifi-
cant difference in health system costs between the 2 arms (S8 Table). From a wider societal per-
spective, which combines impacts on the health system with impacts on productivity costs, the
HAP plus EUC arm had significantly lower costs at 12 months (mean difference = −$154.93;
95% CI −$305.51, −$4.35; p = 0.044). This was due to lower costs of days out of work and work
cutback (mean difference = −$146.28; 95% CI −$218.08, −$74.47; p< 0.001). While there is still
a gain in mean QALYs per person at 12 months compared to at 3 months, this difference was
not quite statistically significant (mean difference = 0.011; 95% CI 0.006, −0.002; p = 0.092).
Table 3 provides an assessment of cost-effectiveness showing ICERs. It indicates that the incre-
mental cost per QALY gained is −$1,721; thus, HAP plus EUC is associated with both lower
costs and better outcomes than EUC alone. To test the robustness of the ICER results, 2 cost-
Table 2. Effect of HAP plus EUC compared with EUC alone on disability and intimate partner violence at 12 months.
Outcome EUC arm (n =
248)
HAP + EUC arm (n =
245)
Measure: point estimate (95% CI)1 p-Value
Mean disability score (SD) 10.89 (9.22) 9.38 (9.61) AMD: −1.58 (−3.33, 0.17); ES: 0.16 (0.12,
0.19)
0.08
Mean days unable to work (SD) 6.05 (8.81) 4.81 (8.24) AMD: −1.29 (−2.89, 0.31); ES: 0.15 (0.11,
0.19)
0.12
Intimate partner physical violence*—females 20/118 (16.57%) 11/109 (9.86%) PR: 0.60 (0.29, 1.22) 0.16
Intimate partner psychological/emotional violence*—
females
40/118 (33.86%) 28/109 (26.10%) PR: 0.75 (0.50, 1.13) 0.17
Intimate partner psychological/emotional violence*—
males
12/40 (28.75%) 7/34 (19.23%) PR: 0.82 (0.36, 1.84) 0.62
Data given as number (percent) unless otherwise indicated.
1AMD adjusted for primary health centre as a fixed effect and Patient Health Questionnaire 9 baseline score.
*Among married participants.
AMD, adjusted mean difference; ES, effect size; EUC, enhanced usual care; HAP: Healthy Activity Programme; PR, prevalence ratio.
https://doi.org/10.1371/journal.pmed.1002385.t002
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effectiveness analysis planes were generated using 1,000 randomly resampled pairs of costs and
QALY outcomes from both the health system and societal perspectives to generate further val-
ues of incremental cost per QALY gained (Fig 5). This can help policymakers by showing the
likelihood that any intervention will be cost-effective or even cost-saving. Fig 5A indicates that
HAP plus EUC has a 58% chance of being cost-saving from a health system perspective, i.e.,
58% of the 1,000 pairs of costs and QALYs are in the southeast quadrant, which indicates that
the intervention (in this case HAP plus EUC) has both lower costs and better QALY outcomes
Fig 4. The mediating effect of behavioural activation at 3 months on the effectiveness of the HAP on depression
severity at 12 months. Variables as follows: β, Beta coefficient; a, a-path (HAP–mediator); b, b-path (mediator–outcome);
c, direct effect (HAP–outcome); a × b, indirect effect. BDI-II, Beck Depression Inventory–II; PHQ-9, Patient Health
Questionnaire 9.
https://doi.org/10.1371/journal.pmed.1002385.g004
Table 3. Cost-effectiveness analyses from health system and societal perspectives (costs in 2015 international dollars).
Category Health system perspective Societal perspective
Cost (95% CI) Likelihood ICER is CS and CE Cost (95% CI) Likelihood ICER is CS and CE
Per QALY gained at 12
months*
−1,721 (−23,966,
18,158)
CS: 58%; CE: 95% −14,438 (−81,359,
13,966)
CS: 98%; CE: 99%
Per remission at 12 months** −149 (−1,304, 988) CS: 59%; CE: 90% −1,250 (−3,869, −186) CS: 99%; CE: 100%
*Assumes willingness to pay threshold equivalent to GDP per capita in Goa ($16,060).
**Assumes willingness to pay threshold equivalent to 1 month’s wages for unskilled manual worker in Goa ($415).
CE, cost-effective; CS, cost-saving; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
https://doi.org/10.1371/journal.pmed.1002385.t003
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than EUC alone, while a further 39% of the 1,000 pairs of costs and QALYs fall in the northeast
quadrant, where HAP plus EUC is more effective but more expensive than EUC alone. Nearly
all of the observations in this quadrant were still below the cost-effectiveness threshold used in
the analysis (shown by the red line) of GDP per capita per additional QALY gained, a threshold
which has been applied in economic evaluations in LMICs [42]. This threshold in the state of
Goa expressed in international dollars in 2015 was $16,060 [43]. Overall, this means that the
case for investment is very strong, with a 95% likelihood that investment in the intervention will
be cost-effective, including a 58% chance that it will be cost-saving. Similarly, in Fig 5B when
costs also include a conservative estimate of productivity losses to patients and families, 98% of
the pairs of costs and QALYs fall in the southeast quadrant, where HAP plus EUC is cost-saving
with lower costs and better outcomes compared to EUC alone. As Table 3 shows, if the same
approach is used to look at costs per additional remission achieved compared to EUC from a
health system perspective, HAP plus EUC would be considered a highly worthwhile investment
(S2 Fig), with a 90% chance of being cost-effective, including a 59% chance of being cost-saving.
Discussion
We report on the sustained effects, the cost-effectiveness, and the role of behavioural activation
in mediating the effectiveness of HAP, a brief PT delivered by lay counsellors to primary care
attendees with moderately severe to severe depression in a randomised controlled trial in
India. We have 2 main findings.
Our first main finding was that the effects of HAP on acute depression observed shortly
after the end of treatment (3 months post-enrolment) were largely sustained through the
Fig 5. Cost-effectiveness planes: HAP plus EUC compared to EUC. (A) Health system perspective; (B) societal perspective. EUC, enhanced usual care;
HAP, Healthy Activity Programme; QALY, quality-adjusted life year.
https://doi.org/10.1371/journal.pmed.1002385.g005
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12-month follow-up. This is striking because depression tends to return after treatment termi-
nation among recently remitted patients, which is one of the reasons physicians are encour-
aged to keep patients on active medications for at least 4 months following initial remission
[23]. What makes this finding less surprising is that HAP is adapted from behavioural activa-
tion, and this approach was found to reduce the risk for subsequent relapse by more than half
relative to prior medications in the one study in which they have been compared [44]. Patients
who remitted on HAP in the short term were more likely to relapse following treatment termi-
nation than patients who remitted in EUC, but that is to be expected since more patients
remitted on HAP than in EUC, and it is plausible that those additional remitters were patients
at higher risk (Fig 3). That being said, HAP’s effects were relatively stable over time (i.e.,
depression severity scores did not change), and the absolute relapse rate was lower than that
observed for behavioural activation in the largest comparable trials [44]. In a disorder that is
prone to relapse, this finding augers well for the possibility that HAP might have an enduring
effect.
Our second major finding was that HAP essentially pays for itself and more. It cost $65.66
per patient to provide HAP, but that extra treatment cost was completely offset by reductions
in other healthcare expenses over the course of a year, so that healthcare costs between the 2
trial arms were no longer significantly different at 12 months (they had been significantly
higher for HAP plus EUC in the 3-month analysis [16]). Moreover, there was a very high prob-
ability (95%) of HAP plus EUC being cost-effective from a health system perspective, including
a 58% probability that it would be costsaving. What our data suggest therefore is that the initial
additional costs of providing HAP will be at least budget neutral from a health system perspec-
tive, while improving clinical outcomes.
When we factor in societal costs in terms of productivity, the economic benefits of HAP
become even more evident. Poor mental health has been associated with significantly lower
rates of participation in employment in low-, middle-, and high-income countries, including
in India, where severe mental illness has been associated with a 40% reduction in individual
earnings [45]. Poor mental health also reduces the opportunity to contribute in other ways to
the economy, such as household activities; it also increases the use of informal care and sup-
port from families. Our analysis also indicates that major gains are made in terms of productiv-
ity that have real implications for the individuals involved and for the larger society in which
they are embedded. The United Kingdom has committed over £700 million to train therapists
to deliver empirically supported treatments like behavioural activation on the premise that
doing so would be good for the economy [46]. Our data suggest that this assumption might
well hold for this Indian setting, despite the substantial structural differences that mean that
the interventions and their contexts are not directly comparable.
Additionally, we observed that patients who received HAP reported feeling better subjec-
tively at 12 months post-enrolment than patients who received EUC alone. Not only were
HAP patients better in terms of reported symptoms, but they had the subjective sense that they
were better in ways that actually mattered to them. This adds a patient-centred outcome to our
main effectiveness results. At the same time, our mediation analysis suggested that patient-
reported levels of behavioural activation at 3 months mediated the effects of HAP in reducing
depression severity at 12 months. This suggests that behavioural activation may underlie
HAP’s sustained effects and, thus, adds to existing evidence suggesting that patient-reported
activation levels mediate response to behavioural activation therapy as specified by theory
[47,48].
Our effects were modest and about a third of patients treated with HAP remained at least
moderately symptomatic. That being said, HAP was a very brief treatment by western stan-
dards (only 6–8 sessions) and was delivered by lay counsellors; most efficacy trials provide 2–3
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times that many sessions delivered by highly trained professionals [49,50]. Treatment differ-
ences did narrow over time from the 3-month post-enrolment assessment to the 12-month fol-
low-up, but that was largely a function of continued improvement in the EUC arm (likely due
to spontaneous remission) and not any loss of efficacy for HAP over time (within-condition
changes were not significant). Even the elevated relapse rate for HAP plus EUC relative to
EUC alone was limited to partial relapse (requiring a change of as little as a point to rise to 10
or above on the PHQ-9); there were no differences with respect to full relapse (scores of 15 or
above). Notwithstanding these notable benefits, it is clear that HAP is not sufficient as a stand-
alone treatment for depression for a sizeable minority of patients in primary care. Whether its
dosage or duration needs to be extended or non-responders switched to or augmented with
another treatment (like medications) remains to be determined.
We acknowledge limitations of this study design. First, from a methodological perspective,
we had only 2 assessment time points, at 3 months and 12 months, thus precluding detection
of possible episodes of remission and relapse between these 2 time points [51]. Second, we con-
tinue to observe a pattern of discordance between our 2 primary outcome measures at 12
months similar to what we found in our 3-month outcome assessments: patients at 12 months
were at the low end of the moderate range of severity on the BDI-II, but the same patients
were indicated as having mild residual symptoms on the PHQ-9. This suggests potential cross-
cultural challenges with the use of the BDI-II, which we are currently investigating in a sepa-
rate report. Third, and according to the sequential ignorability assumption [52], there is a
chance that there may be other confounders that we did not assess that may explain the rela-
tion between the proposed mediator (in this case, patient activation) and depression outcomes.
While our proposed mediator was selected a priori and was based on the conceptual theory of
behavioural activation, future studies considering additional mediators through, for example,
comprehensive structural equation models are required to verify our findings and address the
sequential ignorability assumption [53]. Lastly, we did not apply diagnostic criteria in recruit-
ing patients at baseline or in our definition of outcome, but we note that the PHQ-9 is widely
used to define case-level morbidity in trials and, importantly, we used locally validated cutoffs
in this study [29].
Clinical implications and conclusions
In conclusion, our findings are consistent with the small but growing body of evidence sug-
gesting an enduring effect for behavioural activation or more cognitive behavioural ap-
proaches [44,50,54]. HAP is unique in that, despite its brevity and delivery by a lay counsellor,
it is able to sustain short-term gains in a primary care setting in a lower-middle-income coun-
try. In addition, HAP is only 1 of 2 [55] brief PTs based on behavioural activation theory deliv-
ered by lay counsellors in primary care settings yet evaluated. The low levels of ADM use
noted in our study, even after the diagnosis was conveyed to the primary care physician, con-
firms that the effect of HAP could not have been confounded by ADM use, and further sup-
ports the applicability of the HAP treatment in this treatment-naïve population. The ecological
validity of the trial was enhanced by the fact that the lay counsellors had no prior professional
mental health training (as would be the case in most real-world settings) and that they were
concurrently delivering a completely different PT for harmful drinking (as would be the case
in actual practice) [56]. The importance of establishing sustained effects of treatments cannot
be overemphasised given that depression tends to relapse or recur. We have demonstrated that
brief PTs like HAP and CAP delivered by non-specialist mental health workers in routine pri-
mary care can have sustained clinical effects and are good value for the money. Such treat-
ments are ideal for scaling up, and future research should focus on (1) employing Sequential
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Multiple Assignment Randomized Trial (SMART) designs to assess how different interven-
tions can be applied in sequence to achieve higher rates of remission and recovery [57] and (2)
examining the potential roles of multiple mediators within randomised trial designs so that the
effectiveness of treatments can be enhanced through a focus on these mediators.
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